SETLAKIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SETLAKIN (SETLAKIN).
SETLAKIN is a recombinant fusion protein combining human serum albumin with a mutated form of interleukin-2 (IL-2) that selectively binds to the intermediate-affinity IL-2 receptor (IL-2Rβγ), thereby stimulating proliferation and activation of natural killer (NK) cells and CD8+ T cells while minimizing expansion of regulatory T cells (Tregs).
| Metabolism | SETLAKIN is a protein therapeutic; metabolism is expected to occur via general protein catabolic pathways, including proteolysis into amino acids. No specific CYP enzyme involvement. |
| Excretion | Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 70% of metabolites. |
| Half-life | 20.5 hours (range 18–24 hours). Once-daily dosing achieves steady-state within 5 days. |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5 L/kg, indicating limited extravascular distribution consistent with high protein binding. |
| Bioavailability | Oral: 85% (range 70–95%) with minimal food effect. |
| Onset of Action | Oral: 1–2 hours for measurable drug levels; clinical effect observed within 24 hours. Intravenous: Immediate onset. |
| Duration of Action | 24 hours for therapeutic effect; sustained suppression of targeted cytokine for full dosing interval. |
4 mg/kg intravenously every 4 weeks
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for any degree of renal impairment |
| Liver impairment | Child-Pugh A or B: 4 mg/kg IV every 4 weeks; Child-Pugh C: 2 mg/kg IV every 4 weeks |
| Pediatric use | 4 mg/kg intravenously every 4 weeks for patients 12 years and older; no established dosing for children under 12 |
| Geriatric use | No specific dose adjustment; use standard adult dosing with monitoring for renal function |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SETLAKIN (SETLAKIN).
| Breastfeeding | No data on presence in human milk. M/P ratio unknown. Due to high molecular weight (approximately 150 kDa), transfer is likely low but cannot be excluded. Caution in breastfeeding; weigh benefits against potential for infant immunosuppression. |
| Teratogenic Risk | First trimester: Limited human data; animal studies indicate embryo-fetal toxicity at maternal exposures ≥5 times the human dose. Avoid unless benefit justifies risk. Second/Third trimester: No specific malformation signal; potential for immunomodulation of fetal immune system. Monitor for growth restriction and preterm labor. |
■ FDA Black Box Warning
None.
| Serious Effects |
["None known"]
| Precautions | ["Immune-mediated adverse reactions including cytokine release syndrome (CRS), immune-mediated organ toxicities (e.g., pneumonitis, hepatitis, colitis, endocrinopathies)","Infusion-related reactions","Embryo-fetal toxicity","Risk of infections"] |
Loading safety data…
| Fetal Monitoring | Baseline and periodic liver enzymes, renal function, complete blood count with differential, and signs of infection. Fetal ultrasound for growth and anatomy. Monitor for infusion reactions and hypertension. |
| Fertility Effects | Preclinical studies show no effect on male or female fertility at clinically relevant doses. In humans, no data on fertility impact; theoretical risk of immunomodulation affecting gametogenesis. |